Please assess the completion status of the following clinical trial:

Trial Title: Alternative Dosing Regimens in the Pharmacotherapy of Insomnia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. age between 18 years to 69 years~2. fluent in German language~3. provide written informed consent~4. ability to understand the explanations and instructions given by the study physician and the investigator~Exclusion Criteria:~1. Sleep disorders caused by medical factors (e.g. sleep apnea, restless legs syndrome, narcolepsy, substance-induced insomnia)~2. Contraindications to study medication intake according to the information sheet for health professionals (Summary of medicinal Product Characteristics, SmPC; Fachinformation in Germany) assessed by physical examination (including ECG) and medical history~   * allergies to amitriptyline hydrochloride or any of its ingredients~  * allergies to zolpidem or any of its ingredients~  * acute intoxication with alcohol, analgetics, hypnotics or any other psychotropic drug~  * urinary retention~  * delirium~  * untreated closed-angle glaucoma~  * prostatic hyperplasia~  * pyloric stenosis~  * paralytic ilius~  * suicidal thoughts~  * liver/ kidney/ pulmonary insufficiency~  * myasthenia gravis~  * hypokalemia~  * bradycardia~  * coronary heart disease, cardiac arrhythmias, long QT syndrome or other clinically relevant cardiac disorders~  * increased risk of seizures/ history of seizures~  * substance dependence syndrome/ history of substance dependence syndrome~3. Allergies to ingredients of placebo or novel-tasting drink (CS)~4. currently pregnant (verified by urine pregnancy test) or lactating~5. patients scoring ≥12 on the Epworth Sleepiness Scale~6. patients scoring below 8 or above 21 on the Insomnia Severity Index~7. patients suffering from a mental disorder as verified by the SCID (major depression; psychosis; brain injury; substance abuse or dependency syndrome during the last 6 months before V1)~8. nicotine consumption \> 10 cigarettes/day~9. unwillingness to refrain from alcohol consumption throughout the study~10. Concomitant medication interfering with study medication intake due to potential interactions (all psychotropic medication including analgetics and muscle relaxants, hypericum derivatives; antihypertensives; anti-arrhythmic agents; antibiotics; cisaprid; anti-malaria drugs; diuretics; imidazole antifungals; cumarin derivatives; antihistaminics; calcium channel blockers; medications that enlarge the QT interval or may lead to hypokalemia)~11. change in concomitant medication regime during the last 2 weeks prior to visit 1 or after randomization~12. intake of psychotropic medication during the last 3 months~13. participation in any other clinical trial 3 months prior to visit 1~14. women of childbearing age not using 2 highly effective contraceptive methods~15. employee of the Sponsor or the principal investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- Amitriptyline flexible dosing (Type: EXPERIMENTAL): 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights/placebo
- Zolpidem flexible dosing (Type: EXPERIMENTAL): 5 mg capsule zolpidem before going to bed on 8 out of 17 nights/placebo
- Amitriptyline fixed dosing (Type: ACTIVE_COMPARATOR): 50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
- Zolpidem fixed dosing (Type: ACTIVE_COMPARATOR): 5 mg capsule zolpidem before going to bed on 8 out of 17 nights
- Amitriptyline continuous dosing (Type: ACTIVE_COMPARATOR): 50 mg capsule amitriptyline before going to bed on 13 out of 17 nights

Based on this trial design, predict the completion outcome and termination type (if applicable).